| Titolo | Fase | Stato | Sede patologia | Strutture coinvolte | Dettaglio |
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (ENGOT-en23/GOG3095) |
III |
in corso |
Carcinoma endometriale |
- SC Oncologia Clinica Sperimentale Uro - Ginecologica |
|
A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial |
II |
in corso |
TUMORI GASTROENTEROPANCREATICI (GEP) |
- SC Oncologia Clinica Sperimentale dei Sarcomi e Tumori Rari |
|
Potenziale ruolo protettivo degli inibitori di SGLT-2 sulla cardiotossicità indotta da chemoterapia (PROTECT trial) |
II |
in corso |
Cancro della mammella |
- SC Cardiologia |
|
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical) |
III |
in corso |
Cancro della cervice uterina localmente avanzato |
- SC Oncologia Clinica Sperimentale Uro - Ginecologica |
|
A PHASE III, OPEN-LABEL, RANDOMISED STUDY OF NEOADJUVANT DATOPOTAMAB DERUXTECAN (DATO-DXD) PLUS DURVALUMAB FOLLOWED BY ADJUVANT DURVALUMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY FOLLOWED BY ADJUVANT PEMBROLIZUMAB WITH OR WITHOUT CHEMOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED TRIPLE-NEGATIVE OR HORMONE RECEPTOR-LOW/HER2-NEGATIVE BREAST CANCER |
III |
in corso |
CARCINOMA MAMMARIO |
- SC Oncologia Clinica Sperimentale di Senologia |
